Hepatitis B Surface Antibody Immunity (Quantitative)

Description

This assay is used to determine immune status for Hepatitis B as ≥10 mIU/mL as per CDC Guidelines. Hepatitis B surface antibody quantitation is used to determine hepatitis B immune status, ie, to determine if the patient has developed immunity against the hepatitis B virus. Such immunity may develop following exposure to the hepatitis B virus or its vaccine.

Patients at higher risk of exposure to the virus include:

  • Infants born to infected mothers
  • Sex partners of infected persons
  • People with more than 1 sex partner in the last 6 months
  • People with a history of sexually transmitted infection
  • Men who have sex with men
  • Injection drug users
  • Household contacts of an infected person
  • Healthcare and safety workers who have contact with blood and body fluids
  • People who have lived or traveled in an area in which hepatitis B is common
  • People who live or work in a prison

Testing is not recommended routinely following vaccination. It is advised only for people whose subsequent clinical management depends on knowledge of their immune status. These people include:

  • Chronic hemodialysis patients
  • Immunocompromised people, including those with HIV infection, hematopoietic stem-cell transplant recipients, and people receiving chemotherapy
  • Infants born to women who test positive for the hepatitis B surface antigen
  • Sex partners of people who test positive for the hepatitis B surface antigen
  • Healthcare and public safety workers who have contact with blood or body fluids

Hepatitis B Surface Antibody Immunity (Quantitative)

$31

Average competitors price

$99

Pricing based on average direct to consumer pricing.
  • Fasting Required: NO
  • Preferred Specimen: Serum
  • Reference Range(s): ≥10 mIU/mL
  • Turnaround Time: 4 Days
  • Test Code: 8475